Genmab reports phase 3 success for Elahere competitor and previews Merus buyout data

Genmab disclosed at the European Society for Medical Oncology meeting that its experimental therapy, positioned as a rival to Elahere, achieved a positive outcome in a phase 3 trial.

The result signals a potential new option in the therapeutic area and could influence market dynamics for the drug class.

The company also announced that updated data from two phase 2 studies linked to its recent Merus acquisition will be presented in the coming weeks.

Genmab noted that the forthcoming data will be shared in Spain, highlighting an expansion of its clinical activities in that market.